Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 409
Selected: 0
NCT IDTitle
NCT05651724Global Research Initiative for Patients Screening on MASH
NCT00673920A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy
NCT01752335Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis
NCT01633346Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients
NCT00170170Risk Factors for Cytomegalovirus Disease in Solid Organ Transplantation
NCT00552201TACrolimus in Renal Transplantation: Individualization by Pharmacogenetic
NCT05754502Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy
NCT01101295The ITP-RITUX Cohort: Rituximab in Immune ThrombocytoPenia.
NCT03697850Atezolizumab After Chemo-radiotherapy for MIBC Patients Not Eligible for Radical Cystectomy
NCT01944943Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia
NCT00719264Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
NCT00333736Study to Assess Safety and Quality of Life of Patients Using Biojector Versus Needles for Fuzeon Administration
NCT01223547Study of the Effects of Carbohydrate Counting
NCT04470947Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies
NCT02666898Phase II Trial GA101 Inbrutinib B CLL
NCT01457144Study of Mantle Cell Lymphoma Treatment by RiBVD
NCT00273767Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB
NCT00484328Ribavirin, Its Dosing Regime
NCT01558167A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia
NCT01790633Pilot Study Evaluating the Use of Simultaneous HBV, HCV, and HIV Rapid Tests
NCT05118724Atezolizumab in Patients With MSI-h/MMR-D Stage II High Risk and Stage III Colorectal Cancer Ineligible for Oxaliplatin
NCT06663098Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
NCT01118234Rituximab Versus Observation as Maintenance Therapy in Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia)
NCT06068998Molecular Characterization of Penile Cancers in Developing Countries
NCT02308527Activity Study of Bevacizumab With Temozolomide ± Irinotecan for Neuroblastoma in Children
NCT05798156Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT00166712A Trial of Two Steroid-Free Approaches Toward Mycophenolate Mofetil-Based Monotherapy Immunosuppression
NCT00973609Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)
NCT00217152A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
NCT05283213Development of an Innovative Clinico-biological Score for the Early Detection of Acute Renal Failure Associated With Cardiac Surgery.
NCT02738580Follicular Steroid Genesis in Controlled Ovarian Stimulation
NCT05075538COVID-19: Immune Response in Patients With Cancer Undergoing mRNA Vaccination Against SARS-CoV-2
NCT03802604Combination of Talimogene Laherparepvec With Atezolizumab in Early Breast Cancer
NCT00177255A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
NCT02636452Cardiopulmonary Exercise Testing in Interstitial Lung Disease
NCT01028092mTor-inhibitor (EVERolimus) Based Immunosuppressive Strategies for CNI Minimisation in OLD for Old Renal Transplantation
NCT00440167Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine
NCT04770272Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy
NCT04993274Sensitivity of Motor Assessment in MS - a Prospective Cohort Study
NCT00453362A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib
NCT03679455A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1
NCT03421288Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune Responsiveness
NCT00201734Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary
NCT00407732Overcoming Psychiatric Barriers to the Treatment of Hepatitis C
NCT02739594Comparison of Ibandronate - Zoledronate Regarding Nephrotoxicity in Multiple Myeloma
NCT05689671Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
NCT04984811NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NCT01022541Capecitabine and Oxaliplatin Plus Bevacizumab as Neoadjuvant Treatment for Untreated Unresectable Liver-only Metastases From Colorectal Cancer
NCT04484636PLATON - Platform for Analyzing Targetable Tumor Mutations (Pilot-study)
NCT01817452A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol